טוען...
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine
Lapatinib and capecitabine (L-CAP) is effective in HER-2 positive patients with metastatic breast cancer (MBC). However, moderate to severe diarrhea and rash (≥ grade 2) are problematic dose limiting toxicities. Since risk may vary over the course of therapy, we developed repeated measures models to...
שמור ב:
| Main Authors: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer US
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4173070/ https://ncbi.nlm.nih.gov/pubmed/25216762 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3126-0 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|